Bustling Pipeline for Diabetes and Its Metabolic Consequences

July/August 2008, Vol 1, No 6 - Meeting Highlights
Wayne Kuznar

A number of drugs in late stages of development were featured at the 2008 annual meeting of the American Diabetes Association.
 

SGLT-2 Inhibitors


Sodium glucose contransporter type 2 (SGLT-2) inhibitors, which reduce glucose levels by increasing kidney excretion of glucose, is a novel class designed to treat hyperglycemia.

Dapagliflozin is the first SGLT-2 inhibitor in a phase 3 clinical trial. In patients with type 2 diabetes, dapagliflozin reduces fasting glucose levels by about 20 mg/dL versus placebo and improves oral glucose tolerance. By 12 weeks, hemoglobin (Hb)A1C levels decline by 0.7% to 0.9% (from a baseline of 7.1% to 8.0%). Patients using dapagliflozin have lost an average of 2.5 to 3.5 kg of body weight.

Potential side effects of dapagliflozin include polyuria, recurrent urinary tract infections, salt wasting/dehydration, and electrolyte imbalance/depletion.
 

Exenatide


A long-acting once-weekly formulation of exenatide was found in an open-label, 30-week phase 3 trial to significantly improve HbA1C and fasting plasma glucose from baseline. More patients using once-weekly exenatide achieved an HbA1C of )7% than patients using exenatide twice daily (67% vs 61%; P = .004).

A second study showed that twice-daily exenatide was effective as monotherapy in reducing HbA1C and causing weight loss. A new drug application (NDA) has been submitted for twice-weekly exenatide as stand-alone therapy (it is currently only indicated for use with oral antidiabetic agents).
 

Liraglutide


Liraglutide, a once-daily human glucagon-like peptide-1 analog, significantly reduced HbA1C levels in a 26-week phase 3 trial of 1091 patients with type 2 diabetes previously treated with oral antidiabetic drugs. In contrast to the combination of metformin and glimepiride, liraglutide resulted in weight loss and few episodes of hypoglycemia.
 

More DPP-IV Inhibitors


Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-IV) inhibitor being developed as a once-daily oral treatment for type 2 diabetes. Several phase 3 trials of alogliptin as monotherapy and in combination with insulin, metformin, sulfonylureas, or pioglitazone showed improvements in glycemic control as monotherapy or as add-on therapy.

As monotherapy, alogliptin was superior to placebo in reducing HbA1C levels in a 12-week randomized, double-blind, dose-ranging study of 223 patients with type 2 diabetes. It was not associated with weight gain.

When added to insulin, alogliptin significantly improved glycemic control as early as week 4 in a 26-week randomized, placebo-controlled, double-blind phase 3 international trial of 390 patients with type 2 diabetes.

Saxagliptin is a reversible inhibitor of DPP-IV with dual routes of clearance that is being studied as oncedaily treatment. In a 24-week placebo-controlled phase 3 study of 401 patients with type 2 diabetes, saxagliptin monotherapy was associated with significant reductions in HbA1C, fasting plasma glucose, and postprandial glucose in treatment-naïve patients. An NDA for saxagliptin was submitted at the end of July.
 

New Fibrate for Mixed Dyslipidemia


When used in combination with rosuvastatin, an investigational fenofibric acid molecule (ABT-335), submitted for approval to the US Food and Drug Administration, treats mixed dyslipidemia in patients with type 2 diabetes better than rosuvastatin alone.

The combination of ABT-335 and rosuvastatin was evaluated in 276 patients with type 2 diabetes and mixed dyslipidemia.

ABT-335 plus 10 mg rosuvastatin increased high-density cholesterol by 21% compared with a 6.6% increase with 10 mg of rosuvastatin alone (P = .001) and decreased triglycerides by 44.7% compared with 37.1% with 10 mg rosuvastatin monotherapy. ABT-335 plus 20 mg rosuvastatin was also significantly superior to 20 mg rosuvastatin alone.

A fixed-dose combination of ABT-335 and rosuvastatin is in development, for which an NDA is expected to be submitted in 2009.

Related Items
Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019 in Lymphoma
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019 in Leukemia
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019 in Emerging Therapies
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019 in Emerging Therapies
Last modified: July 20, 2010
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME